Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Inari Medical Inc

Healthcare US NARI

NoneUSD
0.00(0%)

Last update at 2025-03-18T19:03:36.271650Z

Day Range

--
LowHigh

52 Week Range

36.7371.85
LowHigh

Fundamentals

  • Previous Close 79.97
  • Market Cap2920.86M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.78300M
  • Revenue TTM520.66M
  • Revenue Per Share TTM9.04
  • Gross Profit TTM 338.96M
  • Diluted EPS TTM-0.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -26.18500M 10.69M 13.79M -1.19182M -10.15300M
Minority interest - - - - -
Net income -29.26700M 9.84M 13.79M -1.90712M -10.15300M
Selling general administrative 292.84M 190.37M 89.75M 37.20M 10.70M
Selling and marketing expenses - - - - 0.00009M
Gross profit 338.96M 252.23M 126.56M 45.22M 5.55M
Reconciled depreciation 7.12M 4.31M 1.39M 0.61M 0.28M
Ebit -28.09900M 6.67M 18.42M 0.80M -9.18100M
Ebitda -18.77200M 10.98M 18.24M 1.30M -8.89800M
Depreciation and amortization 9.33M 4.31M -0.17800M 0.50M 0.28M
Non operating income net other - -0.15900M -4.63000M - -
Operating income -28.09900M 6.67M 18.42M 0.80M -9.14000M
Other operating expenses 411.57M 266.14M 121.25M 50.33M 15.97M
Interest expense 0.29M 0.29M 1.14M 0.92M 0.89M
Tax provision 3.08M 0.84M - - -
Interest income 1.85M 0.15M 0.48M 0.09M 0.09M
Net interest income 1.56M -0.14100M -0.65100M -0.83135M -0.79510M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.08M 0.84M -0.91200M 0.72M -0.12600M
Total revenue 383.47M 276.98M 139.67M 51.13M 6.83M
Total operating expenses 367.06M 241.38M 108.14M 44.42M 14.69M
Cost of revenue 44.51M 24.76M 13.11M 5.91M 1.28M
Total other income expense net 1.91M 4.01M -4.63000M -1.99332M -0.21800M
Discontinued operations - - - - -
Net income from continuing ops -29.26700M 9.84M 13.79M -1.19182M -10.15269M
Net income applicable to common shares -29.26700M 9.84M 13.79M -1.19200M -10.15300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 674.24M 504.15M 311.54M 214.09M 44.55M
Intangible assets 150.88M - - - -
Earning assets - - - - -
Other current assets 6.48M 5.31M 5.69M 2.86M 0.51M
Total liab 209.32M 87.15M 72.33M 13.84M 83.69M
Total stockholder equity 464.91M 417.00M 239.21M 200.25M -39.14384M
Deferred long term liab - 0.05M 0.29M 0.38M 1.47M
Other current liab 64.07M 47.20M 35.17M 10.79M 6.32M
Common stock 0.06M 0.05M 0.05M 0.05M 0.00672M
Capital stock 0.06M 0.05M 0.05M 0.05M 0.00672M
Retained earnings -48.48600M -46.85000M -17.58300M -27.42300M -41.21181M
Other liab - - 1.42M - -
Good will 214.34M - - - -
Other assets - 0.59M 0.98M 0.92M 1.81M
Cash 39.21M 60.22M 92.75M 114.23M 23.64M
Cash and equivalents - - - - -
Total current liabilities 76.34M 56.17M 42.51M 13.84M 8.87M
Current deferred revenue - - - - -
Net debt -7.16100M -27.93500M -63.54600M -114.22900M -4.15863M
Short term debt 1.69M 1.31M 0.80M - -
Short long term debt - - - - -
Short long term debt total 32.05M 32.29M 29.21M - 19.48M
Other stockholder equity 504.45M 462.95M 257.14M 227.62M 2.06M
Property plant equipment - 72.36M 16.47M 7.50M 3.33M
Total current assets 235.56M 422.90M 245.20M 205.67M 39.41M
Long term investments - 0.00000M 3.98M - -
Net tangible assets - 417.00M 239.21M 200.25M -39.14400M
Short term investments 76.86M 266.18M 83.35M 49.98M -
Net receivables 70.12M 58.61M 42.35M 28.01M 11.30M
Long term debt - - - - 19.48M
Inventory 42.90M 32.58M 21.05M 10.60M 3.95M
Accounts payable 10.58M 7.66M 6.54M 3.05M 2.55M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 8.88M 0.85M -0.40200M 0.00400M -1.27914M
Additional paid in capital - - - - -
Common stock total equity - - 0.05M 0.05M 0.00672M
Preferred stock total equity - - - - -
Retained earnings total equity - - -17.58300M -27.42300M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.22M 8.89M 0.98M 0.92M 1.81M
Deferred long term asset charges - - - - -
Non current assets total 438.67M 81.25M 66.34M 8.42M 5.14M
Capital lease obligations 32.05M 32.29M 29.21M - -
Long term debt total - - - - 19.48M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -195.21600M -37.37700M -55.43700M -49.97700M -49.97700M
Change to liabilities 1.14M 3.51M 0.50M 1.83M 0.37M
Total cashflows from investing activities -195.21600M -51.02200M -55.43700M -3.14400M -0.75300M
Net borrowings - - -20.25000M 9.86M 9.86M
Total cash from financing activities 177.14M 4.07M 144.12M 10.22M 26.76M
Change to operating activities 6.11M 7.04M 1.68M 3.73M 0.83M
Net income -29.26700M 9.84M 13.79M -1.19182M -10.15300M
Change in cash -32.53000M -21.86500M 90.59M 2.14M 15.11M
Begin period cash flow 92.75M 114.62M 24.03M 21.88M 6.77M
End period cash flow 60.22M 92.75M 114.62M 24.03M 21.88M
Total cash from operating activities -13.97200M 25.49M 1.91M -4.93590M -10.89200M
Issuance of capital stock 174.40M 0.00000M 164.36M 0.00000M 26.92M
Depreciation 7.12M 4.31M 1.39M 0.61M 0.28M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -11.68800M -10.48800M -6.64400M -2.87384M -0.55800M
Change to account receivables -17.03000M -14.36100M -16.70600M -8.95482M -2.16500M
Sale purchase of stock 8.42M 5.56M 164.83M 0.13M 27.01M
Other cashflows from financing activities -5.67900M -1.48500M 10.00M 20.36M 26.76M
Change to netincome 29.50M 25.52M 7.73M 1.86M 0.39M
Capital expenditures 9.95M 13.64M 5.46M 3.14M 0.75M
Change receivables - -14.36100M -16.70600M - -
Cash flows other operating - 8.31M 1.68M - -
Exchange rate changes - -0.40200M - - -
Cash and cash equivalents changes - -21.86500M 90.59M - -
Change in working capital -21.46800M -14.30000M -21.16900M -6.25930M -1.52000M
Stock based compensation 28.67M 25.45M 3.52M 0.50M 0.25M
Other non cash items 0.97M 0.14M 0.18M 0.10M 0.11M
Free cash flow -23.92300M 11.84M -3.54800M -8.08004M -11.64500M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NARI
Inari Medical Inc		 - -% - - 1428.57 4.79 5.08 4.62 150.13
ABT
Abbott Laboratories		 2.58 2.97% 89.57 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 3.14 1.06% 298.14 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 3.30 4.23% 81.25 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.81 1.71% 48.51 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Inari Medical Inc

6001 Oak Canyon, Irvine, CA, United States, 92618

Key Executives

Name Title Year Born
Mr. William H. Hoffman CEO, Pres & Director 1967
Mr. Mitchell C. Hill Chief Financial Officer 1959
Mr. Andrew J. Hykes Chief Operating Officer 1973
Dr. Thomas M. Tu M.D. Chief Medical Officer 1973
Ms. Janet Byk VP of Fin. & Accounting NA
Ms. Angela Ahmad Gen. Counsel & Sec. NA
Mr. Eric Khairy Sr. VP of Marketing NA
Mr. John R. Borrell Sr. VP of Sales 1967
Ms. Dena Truelove VP of HR NA
Ms. Tara Dunn Sr. VP of Clinical Affairs & Market Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.